• Vanessa Nseir, Antoine Rachas, Michelle Elias, Hélène Francois, Erika Nnang Obada, Hans Kristian Lorenzo, Bernard Charpentier, Antoine Durrbach, and Séverine Beaudreuil.
• IFRNT, Department of Nephrology, Bicêtre Hospital, University of Paris-Sud, Le Kremlin-Bicêtre, France.
• Blood Purif. 2017 Jan 1; 44 (1): 60-65.

BackgroundThe optimal management of anticoagulation in hemodialyzed patients with a high risk of bleeding is controversial.MethodsWe compared premature termination of dialysis caused by clotting events between AN69ST membranes (G1) and 0.8 mmol/L citrate-enriched dialysate (G2). The number of sessions that had increased venous pressure (VP) and variations in urea-reduction ratio (URR) were analyzed.ResultsSix hundred and two sessions were analyzed in 259 patients: 22.4% had sessions that ended prematurely (25% in G1 and 19.1% in G2, p = ns, OR 0.60 [0.34-1.08], p = 0.08). The increase in VP was lower in G2 (23 vs. 70, p < 0.001). URR was higher in G2 (0.56 vs. 0.60, p < 0.001).ConclusionClotting events that led to the termination of dialysis were comparable in the 2 groups. However, UUR was better in G2, and the number of patients with increased VP in the sessions was lower in G2.Short SummaryOur study compared the effects of the AN69ST membrane and citrate-enriched dialysate on clotting events during the dialysis of 259 patients with a high risk of bleeding. URR was significantly better and fewer cases of increased VP occurred in the citrate group compared to the AN69 ST group. No significant difference was observed regarding the need to prematurely terminate a dialysis session.© 2017 S. Karger AG, Basel.

21 keywords...

hide…